TF Venture Capital Management Co. Ltd. 13D and 13G filings for CELLULAR BIOMEDICINE GROUP, IN:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2020-04-01 09:37 am Unchanged | 2020-03-30 | 13D | CELLULAR BIOMEDICINE GROUP, IN CBMG | TF Venture Capital Management Co. Ltd. | 358,974 1.800% | 0 (Unchanged) | Filing |
| 2020-02-21 4:12 pm Unchanged | 2020-02-21 | 13D | CELLULAR BIOMEDICINE GROUP, IN CBMG | TF Venture Capital Management Co. Ltd. | 358,974 1.800% | 0 (Unchanged) | Filing |